← Back to Search

Radiation Therapy

Adaptive Radiation for Anal Cancer

N/A
Recruiting
Led By Lisa Kachnic, MD
Research Sponsored by Columbia University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Age ≥18 years
Histologically proven, invasive primary squamous, basaloid or cloacogenic carcinoma of the anal canal
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months following the completion of chemoradiation
Awards & highlights

Study Summary

This trial looks at using tailored radiation treatment for locally advanced anal cancer. Daily plans are used to maximize dose to the tumor and minimize dose to surrounding organs.

Who is the study for?
This trial is for adults with advanced anal squamous cell cancer, who are in good health otherwise and have not had prior treatments for this cancer. They must be able to perform daily activities without significant assistance (ECOG ≤2) and agree to use contraception during the study.Check my eligibility
What is being tested?
The study tests a new approach using AI-guided radiation therapy tailored daily, combined with chemotherapy drugs like 5-Fluorouracil, Capecitabine, or Mitomycin-C. It aims to improve targeting of the tumor while protecting healthy tissue.See study design
What are the potential side effects?
Possible side effects include skin reactions from radiation, fatigue, nausea from chemotherapy drugs, low blood counts increasing infection risk, and potential liver function changes.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 18 years old or older.
Select...
My cancer is a specific type of anal cancer.
Select...
My breast cancer is at a specific stage and size according to AJCC 8th edition.
Select...
I can care for myself but may not be able to do active work.
Select...
My blood counts and liver/kidney functions are within normal ranges.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months following the completion of chemoradiation
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 months following the completion of chemoradiation for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Time to plan and deliver treatment fractions.
Secondary outcome measures
Acute Treatment Toxicity
Complete Clinical Response Rate

Trial Design

1Treatment groups
Experimental Treatment
Group I: Chemotherapy and Adaptive Radiation Treatment PlanningExperimental Treatment4 Interventions
Subjects will receive concurrent chemotherapy and radiation as part of their treatment for anal cancer. Subjects will receive standard of care 54 Gy of radiation, 5 days a week for 6 weeks. In addition, subjects will receive standard of care chemotherapy, with mitomycin C (10mg/meters squared IV on Day 1) and 5-Fluorouracil (1000mg/meters squared via IV on days 1-4 and 29-32) or capecitabine (825 mg/meters squared in two divided doses by mouth on days of radiotherapy).
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Capecitabine
2013
Completed Phase 3
~3420
Mitomycin-C
2011
Completed Phase 2
~240
5-Fluorouracil
2012
Completed Phase 3
~7800

Find a Location

Who is running the clinical trial?

Varian Medical SystemsIndustry Sponsor
58 Previous Clinical Trials
3,719 Total Patients Enrolled
VarianUNKNOWN
4 Previous Clinical Trials
406 Total Patients Enrolled
Columbia UniversityLead Sponsor
1,426 Previous Clinical Trials
2,473,788 Total Patients Enrolled

Media Library

Artificial Intelligence Guided Daily Radiotherapy Treatment Planning and Delivery (Radiation Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT05838391 — N/A
Anal Carcinoma Research Study Groups: Chemotherapy and Adaptive Radiation Treatment Planning
Anal Carcinoma Clinical Trial 2023: Artificial Intelligence Guided Daily Radiotherapy Treatment Planning and Delivery Highlights & Side Effects. Trial Name: NCT05838391 — N/A
Artificial Intelligence Guided Daily Radiotherapy Treatment Planning and Delivery (Radiation Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05838391 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many enrollees are accepted for this research endeavor?

"Correct. According to clinicaltrials.gov, this medical trial was initially published on May 1st 2023 and is still actively recruiting patients at a single location with the aim of enrolling up to 20 people."

Answered by AI

Is this study currently recruiting participants?

"Clinicaltrials.gov confirms that this trial is actively recruiting participants, with the original posting dated May 1st 2023 and an updated version shared on April 27th 2023."

Answered by AI
~13 spots leftby Dec 2025